Merck's Soaring P/E Masks Patent Cliffs and Pipeline Setbacks, Triggering Institutional Exit

Related Articles

Amgen's Biotech Crossroads: Congressional Divergence Amid Patent Cliffs and Pipeline Promise

1 months ago

What is BioFuel Dynamics' New Patent and Why Does it Matter

4 months ago

Why Are Emerging Markets Suddenly Soaring

6 months ago

Is Big Pharma's Patent Cliff Driving a New M&A Wave

5 months ago

Category

You may also like

Stock News•2 weeks ago

Merck vs. J&J: Which Healthcare Giant Should Investors Choose?

J&J's diversified portfolio and pipeline strength may offer an edge over Merck, as both face patent expiration challenges. Investors weigh JNJ's breadth against MRK's exposure to upcoming losses.

JNJ

Share

Stock News•1 months ago

Merck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less Steep

Merck extended Keytruda's lifecycle via subcutaneous Qlex and exclusivity through 2039, plus acquisitions of Terns and Cidara. The stock rallied 17% since last quarter, with a 2030–32 P/E of ~13.5, re...

MRK

Share

Stock News•1 months ago

Merck (MRK) Stock Sinks As Market Gains: Here's Why

Merck (MRK) fell 1.22% to $123.54 in the latest session, underperforming the broader market gain.

MRK

Share